Compagnie Financiere Richemont SA (GB:0QMU)

Compagnie Financiere Richemont SA (0QMU) Income Statement


Compagnie Financiere Richemont SA Income Statement

Last quarter (Q2 2023), Compagnie Financiere Richemont SA's total revenue was €―, a decrease of ― from the same quarter last year. In Q2, Compagnie Financiere Richemont SA's net income was €―. See Compagnie Financiere Richemont SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 22Mar 21Mar 20Mar 19Mar 18
Total Revenue
-€ 19.18B€ 13.14B€ 14.24B€ 13.99B€ 11.01B
Cost of Revenue
-€ 7.15B€ 5.28B€ 5.63B€ 5.35B€ 3.83B
Gross Profit
-€ 12.03B€ 7.86B€ 8.61B€ 8.64B€ 7.18B
Operating Expense
-€ 8.66B€ 6.38B€ 7.09B€ 6.70B€ 5.34B
Operating Income
-€ 3.37B€ 1.48B€ 1.52B€ 1.94B€ 1.84B
Net Non Operating Interest Income Expense
-€ -120.00M€ -132.00M€ -84.00M€ -53.00M€ -266.00M
Other Income Expense
Pretax Income
-€ 2.58B€ 1.51B€ 1.20B€ 3.17B€ 1.65B
Tax Provision
-€ 498.00M€ 226.00M€ 267.00M€ 381.00M€ 432.00M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
-€ 2.07B€ 1.30B€ 933.00M€ 2.78B€ 1.22B
Basic EPS
-€ 3.66€ 2.30€ 1.65€ 4.93-
Diluted EPS
-€ 3.61€ 2.30€ 1.65€ 4.93-
Basic Average Shares
-€ 566.70M€ 565.20M€ 565.00M€ 564.30M-
Diluted Average Shares
-€ 574.40M€ 566.60M€ 566.80M€ 565.10M-
Dividend Per Share
-€ 1.85€ 0.00€ 1.84€ 0.00-
Total Operating Income As Reported
Reported Normalized Basic E P S
-€ 3.76€ 2.33€ 1.74€ 2.60-
Reported Normalized Diluted E P S
-€ 3.71€ 2.32€ 1.74€ 2.60-
Rent Expense Supplemental
-€ 571.00M€ 397.00M€ 364.00M€ 1.06B€ 991.00M
Total Expenses
-€ 15.82B€ 11.67B€ 12.72B€ 12.05B€ 9.17B
Net Income From Continuing And Discontinued Operation
-€ 2.07B€ 1.30B€ 933.00M€ 2.78B€ 1.22B
Normalized Income
-€ 2.50B€ 1.21B€ 950.80M€ 2.89B€ 1.22B
Interest Expense
-€ 194.00M€ 181.00M€ 192.00M€ 151.00M€ 335.00M
-€ 2.77B€ 1.70B€ 1.39B€ 3.32B€ 1.99B
-€ 4.32B€ 3.22B€ 2.88B€ 4.13B€ 2.53B
Currency in EUR

Compagnie Financiere Richemont SA Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis